Cover Image
市場調查報告書

受體酪胺酸·蛋白激酶 ERBB 3:開發中產品分析

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365768
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
受體酪胺酸·蛋白激酶 ERBB 3:開發中產品分析 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 101 Pages
簡介

本報告提供以受體酪胺酸·蛋白激酶 ERBB 為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,再加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊3。

簡介

  • 調查範圍

受體酪胺酸·蛋白激酶 ERBB 3 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • 第一三共
  • Etubics Corporation
  • F. Hoffmann-La Roche Ltd.
  • GamaMabs Pharma S.A.
  • GlaxoSmithKline Plc
  • Hanmi Pharmaceuticals, Co. Ltd.
  • ImmunoGen, Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Merus B.V.
  • Novartis AG
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Sorrento Therapeutics, Inc.
  • Symphogen A/S
  • Takis S.r.l.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0913TDB

Summary:

According to the recently published report 'Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2017'; Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) pipeline Target constitutes close to 23 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosine-protein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin-1 (NRG1) and is activated by it. It also activated by CSPG5.

The report 'Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2017' outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 5, 2, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Solid Tumor, Melanoma, Metastatic Breast Cancer, Lung Cancer, Pancreatic Cancer, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Lung Adenocarcinoma, Metastatic Colorectal Cancer, Ovarian Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Colorectal Tumor, Endometrial Cancer, Epithelial Tumor, Ewing Sarcoma, Head And Neck Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Mesothelioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Nasopharyngeal Cancer, Neuroendocrine Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Tumor, Peritoneal Tumor, Skin Cancer, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Thyroid Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
  • The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Overview
    • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • AVEO Pharmaceuticals Inc
    • Celldex Therapeutics Inc
    • Daiichi Sankyo Company Ltd
    • Etubics Corp
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline Plc
    • Hanmi Pharmaceuticals Co Ltd
    • Hummingbird Bioscience Pte Ltd
    • ImmunoGen Inc
    • MediaPharma Srl
    • Merrimack Pharmaceuticals Inc
    • Merus NV
    • Novartis AG
    • Shanghai Fosun Pharmaceutical (Group) Co Ltd
    • Sorrento Therapeutics Inc
    • Symphogen A/S
    • Takis Srl
    • XuanZhu Pharma Co Ltd
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Drug Profiles
    • AV-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BA-0702 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CDX-3379 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elgemtumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETBX-031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FCN-411 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2849330 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HMBD-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • huHER3-8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • istiratumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lumretuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MCLA-125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize HER-3 for Breast and Pancrestic Cancers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MPEV-201959 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • patritumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pirotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • poziotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sapitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • seribantumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit EGFR, HER2 and HER3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Sym-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TK-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Dormant Products
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Discontinued Products
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 19, 2017: Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018
      • Apr 03, 2017: AVEO Announces Milestone Payment from CANbridge for AV-203
      • Apr 03, 2017: Hummingbird Bioscience presents update on HMBD-001 at AACR in Washington DC
      • Mar 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
      • Mar 27, 2017: Merrimack to Present Data on Istiratumab (MM-141) at the 2017 American Association for Cancer Research Annual Meeting
      • Dec 08, 2016: Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer
      • Dec 05, 2016: Spectrum Pharmaceuticals Presents Abstract on Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016
      • Nov 17, 2016: Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016
      • Oct 25, 2016: Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer
      • Sep 28, 2016: Merrimack to Present a Poster on Seribantumab (MM-121) at the European Society for Medical Oncology 2016 Congress
      • Aug 26, 2016: CFDA Granted Approval of Phase I-III Clinical Trials for Sirotinib (XZP - 5491)
      • Aug 11, 2016: CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody, CAN-017, for Esophageal Squamous Cell Cancer
      • Jul 06, 2016: FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
      • Jun 06, 2016: Kolltan Pharmaceuticals Presents Clinical Data for KTN3379 in an Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
      • May 31, 2016: Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by AstraZeneca Plc, H2 2017
  • Pipeline by AVEO Pharmaceuticals Inc, H2 2017
  • Pipeline by Celldex Therapeutics Inc, H2 2017
  • Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Pipeline by Etubics Corp, H2 2017
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Pipeline by GlaxoSmithKline Plc, H2 2017
  • Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
  • Pipeline by Hummingbird Bioscience Pte Ltd, H2 2017
  • Pipeline by ImmunoGen Inc, H2 2017
  • Pipeline by MediaPharma Srl, H2 2017
  • Pipeline by Merrimack Pharmaceuticals Inc, H2 2017
  • Pipeline by Merus NV, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H2 2017
  • Pipeline by Sorrento Therapeutics Inc, H2 2017
  • Pipeline by Symphogen A/S, H2 2017
  • Pipeline by Takis Srl, H2 2017
  • Pipeline by XuanZhu Pharma Co Ltd, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Discontinued Products, H2 2017
  • Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top